Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lansoprazole in Zollinger-Ellison Syndrome
NCT00204373Phase 4Completed
- Start
- Mar 2003
- Primary completion
- Dec 2010
- Modality
- Small Molecules
01
Overview
Phase 4, open-label, single-arm trial of lansoprazole in Zollinger–Ellison syndrome (ZES) and multiple endocrine neoplasia (MEN). Primary endpoint: Long-term Medical(Non-surgical)Control of Gastric Acid Production at 240 months. Started Mar 2003; status: completed.
02
Drugs
lansoprazole
03
Conditions
Zollinger–Ellison syndrome (ZES)multiple endocrine neoplasia (MEN)
Beyond the preview
Go deeper on NCT00204373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00204373.